You Position: Home > Paper

Interferon combined with thymosin α1 in the treatment of HBeAg-positive chronic hepatitis B for 52 weeks

( views:0, downloads:0 )
Author:
No author available
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
1
DOI:
10.3760/cma.j.issn.1674-2397.2011.01.012
Key Word:
肝炎,乙型,慢性;干扰素;胸腺素;免疫;Chronic hepatitis B;Interferon;Thymosin;Immunity

Abstract´╝Ü @@ 目前用于治疗慢性乙型肝炎(CHB)的抗病毒药物有两大类,即核苷(酸)类药物和干扰素(IFN),两者均不能彻底清除体内病毒.核苷(酸)类药物服用方便,不良反应小,但需长期服用,且有产生耐药的风险.IFN的疗程明确,HBeAg/抗-HBe血清学转换率相对较高[1],但不良反应较大,病毒学应答率仍有待提高.胸腺素α1具有免疫调节作用.本研究主要观察胸腺素α1是否具有增强IFN抗HBV的作用.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn